Stronger survival data for Kyprolis - Amgen

Amgen Inc said that its licensed drug, Kyprolis (carfilzomib), produced a better survival benefit in a Phase 3 trial of patients with relapsed or refractory multiple myeloma than Velcade (bortezomib). The trial results were published in The Lancet Oncology on 23 August.

Full text available to subscribers only. Click here for information on subscribing to MedNous.


United States